On 23 October 2006, orphan designation (EU/3/06/404) was granted by the European Commission to Gendux AB, Sweden, for adenoviral vector containing human p53 gene for the treatment of Li-Fraumeni syndrome.
The sponsorship was transferred to Gendux Molecular Limited, Ireland, in December 2007.
Adenoviral vector containing human p53 gene
Treatment of Li Fraumeni Syndrome
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: